drugset / Trial / NCT00569114
Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) Patients
Non-randomizedSingle-groupOpen-label
Summary
This is a multicenter, open-label, phase 1, dose escalation study. The purpose is to determine the highest dose of TG01 that can be safely given to patients with Non-Small Cell Lung Cancer in combination with erlotinib.
Timeline
- Start
- 2007-10
- Primary completion
- 2009-04
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | apricoxib | Small molecule | — | Oral |
| Background | Erlotinib | Small molecule | 150 mg | — |